{"id":"W2793526309","doi":"10.1016/s1474-4422(18)30069-3","title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","year":2018,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":337,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; NeuroRx Research (Canada); University of Ottawa; Montreal Neurological Institute and Hospital","funders":"Actelion Pharmaceuticals; Genentech; Acorda Therapeutics; Celgene; Biogen; Sanofi Genzyme; American Academy of Neurology; Bayer HealthCare; Sanofi; National Institute of Neurological Disorders and Stroke; Teva Pharmaceutical Industries; Novartis Pharma; EMD Serono; Ministry of Education; Novartis; Chugai Pharmaceutical; Roche; Genzyme; Pfizer; Amgen; MedDay Pharmaceuticals; National Multiple Sclerosis Society","keywords":"Natalizumab; Multiple sclerosis; Open label; Medicine; Placebo; Double blind; Disease; Clinical trial; Internal medicine; Pathology; Alternative medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002422103,0.0004170355,0.001860739,0.0002526802,0.0002682848,0.00005141833,0.0006665354,0.0001440259,0.00008930277],"category_scores_gemma":[0.001779739,0.0002095159,0.00009729982,0.0003615279,0.0009747919,0.000183157,0.0003955221,0.0007756053,0.00001611772],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003926405,"about_ca_system_score_gemma":0.000223758,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004951023,"about_ca_topic_score_gemma":0.0000850243,"domain_scores_codex":[0.9949732,0.002201401,0.0006009202,0.0008165253,0.0006570175,0.0007509005],"domain_scores_gemma":[0.9958655,0.002011687,0.0004189753,0.001164372,0.0002486627,0.0002907916],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.955265,0.003528701,0.0006758359,0.0001569019,0.0002005559,0.000228572,0.000232888,0.00000555833,0.006084246,0.000008205328,0.0004552044,0.03315836],"study_design_scores_gemma":[0.9007086,0.08554506,0.00277559,0.0003999791,0.0002034587,0.00002166585,0.000009965658,0.003412469,0.006643846,0.000007988848,0.0001015034,0.0001698957],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719669,0.0003398901,0.000005324796,0.002690857,0.0002312583,0.02425484,0.00004009293,0.00007389109,0.0003968932],"genre_scores_gemma":[0.9926526,0.0001145614,0.00008569757,0.0007152605,0.0007183973,0.005567173,0.00005748022,0.00006022041,0.00002859947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08201636,"threshold_uncertainty_score":0.8543809,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1127130527398965,"score_gpt":0.4109636813498584,"score_spread":0.2982506286099619,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}